Monthly Newsletter

Sygnature Discovery Limited, the UK’s largest independent integrated drug discovery provider, today announced the appointment of Dr Gerry Thomas to the pivotal role of Director of Business Development.

Board Director, Dr Paul Clewlow, stated, “I am delighted to welcome Gerry Thomas to Sygnature Discovery.  Gerry is a very experienced industry professional having spent over 20 years in drug discovery and development at Boots Pharmaceuticals, BASF/Knoll, OSI Pharmaceuticals, Prosidion and Shire Pharmaceuticals.  Sygnature Discovery has ambitious plans to expand its customer base and Gerry will be instrumental in promoting Sygnature’s integrated drug discovery capabilities and expertise across Europe and North America.  Gerry is a PhD medicinal chemist with considerable experience and an in-depth knowledge of the drug discovery and development process.”

Dr Gerry Thomas, Director of Business Development, added, “I am pleased to join Sygnature Discovery to work with Paul and his senior scientific colleagues and continue the impressive growth the company has been experiencing over the past 10 years.  I know Sygnature well having been a client and was extremely impressed with their capabilities, expertise and determination to deliver on challenging drug discovery projects.  So, when the opportunity arose, I was very happy to join the company.  I am looking forward to the challenge of promoting Sygnature’s integrated drug discovery services using my know-how and experience in drug discovery and development.”

About Sygnature Discovery 

Sygnature Discovery, founded in 2004 in Nottingham, UK, is a leading provider of integrated drug discovery services to pharmaceutical companies, biotechs and academic groups located in Europe and the USA.  The company employs over 90 laboratory-based, industry-experienced PhD medicinal chemists, computational chemists and in vitro biologists.  Through its unique ‘federated’ CRO model, Sygnature undertakes complete drug discovery programmes and hit identification, lead generation and lead optimisation projects for its clients.  Sygnature has strategic alliances with Proteros (X-ray protein structure analysis), Cyprotex Discovery (ADME/toxicology), Saretius (pre-clinical pain/CNS and metabolic disease models), Pneumolabs (pre-clinical respiratory models), Horizon Discovery (X-Man^TM isogenic cell lines), and ChanTest (ion channel experts) to facilitate the delivery of top quality drug discovery services. 

more about sygnature discovery